Hologic (NASDAQ:HOLX) PT Raised to $82.00 at Evercore ISI

Hologic (NASDAQ:HOLX) had its target price boosted by stock analysts at Evercore ISI from $78.00 to $82.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “in-line” rating on the medical equipment provider’s stock. Evercore ISI’s target price points to a potential upside of 2.80% from the company’s previous close.

A number of other analysts have also commented on HOLX. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a research report on Tuesday. Finally, Stephens restated an “overweight” rating and set a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Hologic Stock Down 1.0 %

HOLX opened at $79.77 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The business has a 50 day moving average price of $81.22 and a 200 day moving average price of $77.38. The firm has a market cap of $18.62 billion, a P/E ratio of 40.70, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic has a twelve month low of $64.02 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the business earned $0.93 earnings per share. Research analysts forecast that Hologic will post 4.09 EPS for the current year.

Insider Activity

In related news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last quarter. 1.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Hologic

Several institutional investors have recently made changes to their positions in HOLX. Massmutual Trust Co. FSB ADV grew its holdings in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares in the last quarter. Graypoint LLC grew its stake in shares of Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after acquiring an additional 147 shares during the period. Sequoia Financial Advisors LLC lifted its position in shares of Hologic by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after acquiring an additional 165 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 189 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its position in shares of Hologic by 0.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock worth $2,425,000 after buying an additional 192 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.